- Home
- GENI vs OGN Comparison
GENI vs OGN Comparison
Compare GENI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- OGN
- Stock Information
- Founded
- GENI 2016
- OGN 1923
- Country
- GENI United Kingdom
- OGN United States
- Employees
- GENI N/A
- OGN N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- GENI Consumer Discretionary
- OGN Health Care
- Exchange
- GENI Nasdaq
- OGN Nasdaq
- Market Cap
- GENI 2.5B
- OGN 2.7B
- IPO Year
- GENI N/A
- OGN N/A
- Fundamental
- Price
- GENI $9.92
- OGN $7.82
- Analyst Decision
- GENI Strong Buy
- OGN Hold
- Analyst Count
- GENI 17
- OGN 4
- Target Price
- GENI $13.76
- OGN $15.75
- AVG Volume (30 Days)
- GENI 6.8M
- OGN 7.0M
- Earning Date
- GENI 11-04-2025
- OGN 11-10-2025
- Dividend Yield
- GENI N/A
- OGN 1.03%
- EPS Growth
- GENI N/A
- OGN N/A
- EPS
- GENI N/A
- OGN 1.91
- Revenue
- GENI $604,524,000.00
- OGN $6,301,000,000.00
- Revenue This Year
- GENI $28.54
- OGN N/A
- Revenue Next Year
- GENI $17.14
- OGN $0.65
- P/E Ratio
- GENI N/A
- OGN $4.05
- Revenue Growth
- GENI 30.70
- OGN N/A
- 52 Week Low
- GENI $8.15
- OGN $6.18
- 52 Week High
- GENI $13.73
- OGN $17.23
- Technical
- Relative Strength Index (RSI)
- GENI 44.01
- OGN 51.31
- Support Level
- GENI $8.59
- OGN $6.95
- Resistance Level
- GENI $10.51
- OGN $7.83
- Average True Range (ATR)
- GENI 0.43
- OGN 0.42
- MACD
- GENI 0.05
- OGN 0.13
- Stochastic Oscillator
- GENI 69.66
- OGN 95.47
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.